251 related articles for article (PubMed ID: 23184698)
21. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
22. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
23. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
24. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B.
Wu J; Richer J; Horwitz KB; Hyder SM
Cancer Res; 2004 Mar; 64(6):2238-44. PubMed ID: 15026368
[TBL] [Abstract][Full Text] [Related]
25. Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges.
McFall T; Patki M; Rosati R; Ratnam M
Oncotarget; 2015 Oct; 6(32):33146-64. PubMed ID: 26356672
[TBL] [Abstract][Full Text] [Related]
26. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III.
Finlay-Schultz J; Gillen AE; Brechbuhl HM; Ivie JJ; Matthews SB; Jacobsen BM; Bentley DL; Kabos P; Sartorius CA
Cancer Res; 2017 Sep; 77(18):4934-4946. PubMed ID: 28729413
[TBL] [Abstract][Full Text] [Related]
27. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
28. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.
Carnevale RP; Proietti CJ; Salatino M; Urtreger A; Peluffo G; Edwards DP; Boonyaratanakornkit V; Charreau EH; Bal de Kier Joffé E; Schillaci R; Elizalde PV
Mol Endocrinol; 2007 Jun; 21(6):1335-58. PubMed ID: 17440047
[TBL] [Abstract][Full Text] [Related]
29. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
30. Progestins and breast cancer hallmarks: The role of the ERK1/2 and JNK pathways in estrogen receptor positive breast cancer cells.
Louw-du Toit R; Simons M; Africander D
J Steroid Biochem Mol Biol; 2024 Mar; 237():106440. PubMed ID: 38048919
[TBL] [Abstract][Full Text] [Related]
31. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth.
Sartorius CA; Harvell DM; Shen T; Horwitz KB
Cancer Res; 2005 Nov; 65(21):9779-88. PubMed ID: 16266999
[TBL] [Abstract][Full Text] [Related]
32. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
Niu F; Wang L; Zhang W; Lyu S; Niu Y
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
[TBL] [Abstract][Full Text] [Related]
33. The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer.
Yu KD; Shen ZZ; Shao ZM
Breast Cancer Res Treat; 2009 Dec; 118(3):661-3. PubMed ID: 19714461
[No Abstract] [Full Text] [Related]
34. Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells.
Diep CH; Charles NJ; Gilks CB; Kalloger SE; Argenta PA; Lange CA
Cell Cycle; 2013 May; 12(9):1433-49. PubMed ID: 23574718
[TBL] [Abstract][Full Text] [Related]
35. RNPC1 enhances progesterone receptor functions by regulating its mRNA stability in breast cancer.
Lou P; Li C; Shi L; Xia TS; Zhou W; Wu J; Zhou X; Li X; Wang Y; Wei JF; Ding Q
Oncotarget; 2017 Mar; 8(10):16387-16400. PubMed ID: 27634883
[TBL] [Abstract][Full Text] [Related]
36. FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences.
Giulianelli S; Riggio M; Guillardoy T; Pérez Piñero C; Gorostiaga MA; Sequeira G; Pataccini G; Abascal MF; Toledo MF; Jacobsen BM; Guerreiro AC; Barros A; Novaro V; Monteiro FL; Amado F; Gass H; Abba M; Helguero LA; Lanari C
Int J Cancer; 2019 Oct; 145(7):1874-1888. PubMed ID: 30843188
[TBL] [Abstract][Full Text] [Related]
37. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
38. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
[TBL] [Abstract][Full Text] [Related]
39. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
[TBL] [Abstract][Full Text] [Related]
40. Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor.
McGowan EM; Russell AJ; Boonyaratanakornkit V; Saunders DN; Lehrbach GM; Sergio CM; Musgrove EA; Edwards DP; Sutherland RL
Cancer Res; 2007 Sep; 67(18):8942-51. PubMed ID: 17875737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
